Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025
Aurinia Pharmaceuticals (NASDAQ: AUPH) has announced that it will release its 2024 fourth quarter and full year financial and operational results on February 27, 2025, before the market opens.
The company's management team will host a conference call and webcast at 8:30 am ET on the same day to review these results and provide a general business update. Interested parties can join the conference call by dialing 877-407-9170 (US) or +1 201-493-6756 (International).
A replay of the webcast will be available on Aurinia's website.
Aurinia Pharmaceuticals (NASDAQ: AUPH) ha annunciato che rilascerà i suoi risultati finanziari e operativi del quarto trimestre del 2024 e dell'anno intero il 27 febbraio 2025, prima dell'apertura del mercato.
Il team di gestione dell'azienda ospiterà una conferenza telefonica e un webcast alle 8:30 am ET nello stesso giorno per esaminare questi risultati e fornire un aggiornamento generale sull'attività. Le parti interessate possono partecipare alla conferenza telefonica componendo il numero 877-407-9170 (USA) o +1 201-493-6756 (Internazionale).
Una registrazione del webcast sarà disponibile sul sito web di Aurinia.
Aurinia Pharmaceuticals (NASDAQ: AUPH) ha anunciado que publicará sus resultados financieros y operativos del cuarto trimestre de 2024 y del año completo el 27 de febrero de 2025, antes de la apertura del mercado.
El equipo de gestión de la empresa llevará a cabo una llamada de conferencia y un webcast a las 8:30 am ET el mismo día para revisar estos resultados y proporcionar una actualización general del negocio. Las partes interesadas pueden unirse a la llamada de conferencia marcando 877-407-9170 (EE. UU.) o +1 201-493-6756 (Internacional).
Una grabación del webcast estará disponible en el sitio web de Aurinia.
Aurinia Pharmaceuticals (NASDAQ: AUPH)는 2024년 4분기 및 연간 재무 및 운영 결과를 2025년 2월 27일, 시장 개장 전에 발표할 것이라고 발표했습니다.
회사의 경영진은 같은 날 오전 8시 30분 ET에 이 결과를 검토하고 일반 사업 업데이트를 제공하기 위해 컨퍼런스 콜과 웹캐스트를 개최합니다. 관심 있는 분들은 877-407-9170 (미국) 또는 +1 201-493-6756 (국제)로 전화하여 컨퍼런스 콜에 참여할 수 있습니다.
웹캐스트의 재생은 Aurinia 웹사이트에서 이용할 수 있습니다.
Aurinia Pharmaceuticals (NASDAQ: AUPH) a annoncé qu'elle publiera ses résultats financiers et opérationnels du quatrième trimestre 2024 et de l'année entière le 27 février 2025, avant l'ouverture du marché.
L'équipe de direction de l'entreprise organisera une conférence téléphonique et un webcast à 8h30 ET le même jour pour passer en revue ces résultats et fournir une mise à jour générale de l'entreprise. Les parties intéressées peuvent rejoindre la conférence téléphonique en composant le 877-407-9170 (États-Unis) ou +1 201-493-6756 (International).
Un enregistrement du webcast sera disponible sur le site Web d'Aurinia.
Aurinia Pharmaceuticals (NASDAQ: AUPH) hat angekündigt, dass es seine finanziellen und operativen Ergebnisse für das vierte Quartal 2024 und das gesamte Jahr am 27. Februar 2025, vor Markteröffnung, veröffentlichen wird.
Das Management-Team des Unternehmens wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um diese Ergebnisse zu überprüfen und ein allgemeines Update zum Geschäft zu geben. Interessierte Parteien können an der Telefonkonferenz teilnehmen, indem sie 877-407-9170 (USA) oder +1 201-493-6756 (international) wählen.
Eine Aufzeichnung des Webcasts wird auf der Website von Aurinia verfügbar sein.
- Aurinia Pharmaceuticals will provide a comprehensive update on its financial and operational performance for Q4 and the full year 2024.
- The company is engaging with investors through a conference call and webcast, indicating transparency and communication.
- None.
Aurinia’s management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business update. The link to the audio webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. A replay of the webcast will be available on Aurinia’s website.
About Aurinia
Aurinia Pharmaceuticals is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) inhibitor for the potential treatment of autoimmune diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250220370017/en/
Media & Investor Inquiries:
Andrea Christopher
Corporate Communications & Investor Relations
Aurinia Pharmaceuticals Inc.
achristopher@auriniapharma.com
General Investor Inquiries:
ir@auriniapharma.com
Source: Aurinia Pharmaceuticals Inc.
FAQ
When will Aurinia Pharmaceuticals release its Q4 and full year 2024 financial results?
What time is the Aurinia Pharmaceuticals conference call for the Q4 and full year 2024 results?
How can I join the Aurinia Pharmaceuticals Q4 and full year 2024 results conference call?
Will there be a replay available for Aurinia Pharmaceuticals' Q4 and full year 2024 results webcast?
What is the stock symbol for Aurinia Pharmaceuticals?
